<DOC>
	<DOCNO>NCT01241591</DOCNO>
	<brief_summary>To evaluate efficacy CP-690,550 compare etanercept safety CP-690,550 treatment moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>A Phase 3 , Multi Site , Randomized , Double Blind , Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Have diagnosis plaque type psoriasis ( psoriasis vulgaris ) ; Have plaquetype psoriasis cover least 10 % total body surface area Considered dermatologist investigator candidate systemic therapy phototherapy psoriasis Nonplaque drug induce form psoriasis Can discontinue current systemic and/or topical therapy treatment psoriasis Can discontinue phototherapy Any uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CP-690,550</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Chronic</keyword>
	<keyword>Plaque</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>OPT Compare</keyword>
	<keyword>OPT</keyword>
	<keyword>head-to-head</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>Psoriasis vulgaris</keyword>
	<keyword>short-term</keyword>
	<keyword>Itch</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>DLQI</keyword>
</DOC>